Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04064060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04064060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Recruiting
Start date
August 12, 2019
Completion date
May 12, 2028
Enrollment
665 (estimated)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, myelodysplastic syndromes (mds), myeloproliferative neoplasm(mpn)-associated myelofibrosis